PLX647

PLX647 is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC50s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC50s=91 and 130 nM, respectively) [1].

Product Specifications

CAS Number

[873786-09-5]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

C-Fms; c-Kit

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PLX647.html

Purity

99.74

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

FC(C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=CC=C43)C=C2)C=C1)(F)F

Molecular Formula

C21H17F3N4

Molecular Weight

382.38

Precautions

H315, H319, H335

References & Citations

[1]Zhang C, et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A. 2013 Apr 2;110 (14) :5689-94.|[2]Louvet C, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008 Dec 2;105 (48) :18895-900.